Continuous Versus Demand-Based Oxygen in Patients With Fibrotic Interstitial Lung Disease and Chronic Obstructive Pulmonary Disease

NCT ID: NCT06767904

Last Updated: 2025-01-17

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-03-01

Study Completion Date

2027-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this randomised clinical trial is to compare the efficacy of exertional oxygen delivery by continous versus demand-based flow systems in patients with fibrotic Interstitial lung disease and chronic obstructive pulmonary disease . The main questions it aim to answer:

Is there a difference in lowest oxygen saturation? Is there a difference in saturation: time below \<90%, pulse rate, distance and patient preferences ? It is a cross over study, so all patients will test both methods. Participants will perform 2 6-minute walk tests with the two different oxygen delivery systems.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study design is a single center, randomized, open-label cross-over exploratory comparative study to investigate the efficacy of two different oxygen delivery systems. Patients with chronic obstructive Pulmonary disease or fibrotic Interstitial Lung Disease that during a six-minute walk test can walk at least 50 m and desaturate below 88%, can be included in the study. The participants are performing 2 6-minute walk tests, randomized to perform the test with oxygen bottles or portable concentrators first. Primary endpoint is the difference in the lowest oxygen saturation between the two systems. Secondary endpoints are amongst others: difference in percentage of time and number of minutes when oxygen falls below 90%, mean and maximum pulse rate, distance and time taken to recover during the 6-minute walk test and scores from questionnaires. After 3-6 months, semistructured interviews will be done to record participants' experiences of ambulatory oxygen therapy.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Interstitial Lung Disease Chronic Obstructive Pulmonary Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Continous oxygen

Oxygen delivery by Continous Oxygen Bottles

Group Type OTHER

Continous Oxygen by Bottles

Intervention Type DEVICE

Oxygen delivery by bottles giving a continous flow.

Demand Based Oxygen

Oxygen Delivery by Demand Oxygen delivery system.

Group Type OTHER

Demand oxygen by Portable Concentrator

Intervention Type DEVICE

Oxygen delivery by consentrators, giving oxygen only when inhaling.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Continous Oxygen by Bottles

Oxygen delivery by bottles giving a continous flow.

Intervention Type DEVICE

Demand oxygen by Portable Concentrator

Oxygen delivery by consentrators, giving oxygen only when inhaling.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥ 18 years
* Verified diagnosis of fibrotic interstitial lung disease or chronic obstructive pulmonary disease
* Desaturation \< 88% during 6-minute walk test or currently receiving ambulatory oxygen by continous oxygen
* Able to walk at least 50 meters during a 6-minute walk test
* Self-reported stable respiratory symptoms in the previous 2 weeks
* Cognitively able to understand and participate in the study
* Written informed consent

Exclusion Criteria

* Any physical condition including paralysis, lower extremity pain, or other musculoskeletal problems limiting exercise performance
* Unstable heart condition or symptomatic stenotic valve disease
* Smoking during the previous 24 hours
* Pregnant women
* Anemia, Hb \< 7.3 mmol/l (women) or \< 8.3 mmol/l (men)
* Non-invasive ventilation
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Sissel Kronborg-White

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Sissel Kronborg-White

Pulmonologist

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Sissel Kronborg-White, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Aarhus University Hospital

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Sissel Kronborg-White, MD, PhD

Role: CONTACT

004524978716

References

Explore related publications, articles, or registry entries linked to this study.

Kronborg-White S, Jensen JH, Bendstrup E, Prior TS. Comparing the efficacy of exertional oxygen delivery by continuous versus demand-based flow systems during 6-minute walk test in patients with fibrotic interstitial lung disease and COPD in a hospital setting (OXYCODE): a protocol for a randomised trial. BMJ Open. 2025 May 16;15(5):e099664. doi: 10.1136/bmjopen-2025-099664.

Reference Type DERIVED
PMID: 40379312 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

OXYCODE

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.